Olfactory Neuroblastoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OLF005 MIFTS: 46	Olfactory Neuroblastoma Categories: Cancer diseases, Neuronal diseases, Rare diseases, Smell/Taste diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Olfactory Neuroblastoma

MalaCards integrated aliases for Olfactory Neuroblastoma:

Name: Olfactory Neuroblastoma ¹² ⁵³ ⁵⁹ ¹⁵ ⁷³

Esthesioneuroblastoma ¹² ⁷⁶ ⁵³ ⁵⁹ ⁵⁵

Paranasal Sinus Olfactory Neuroblastoma ¹²

Esthesioneuroblastoma, Olfactory ⁴⁴

Olfactory Esthesioneuroblastoma ¹²

Esthesioneuroepithelioma ¹²

Asthesioneuroblastoma ¹²

Characteristics:

Orphanet epidemiological data:

⁵⁹

esthesioneuroblastoma
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly;

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Smell/Taste diseases

See all MalaCards categories (disease lists)

ICD10: ³⁴

Neoplasms

Malignant neoplasms of respiratory and intrathoracic organs

Malignant neoplasm of nasal cavity and middle ear

Malignant neoplasm: Nasal cavity

Orphanet: ⁵⁹

Rare neurological diseases

External Ids:

Disease Ontology ¹² DOID:369

MeSH ⁴⁴ D018304

NCIt ⁵⁰ C3789 C6016

SNOMED-CT ⁶⁸ 68614005 76060004

Orphanet ⁵⁹ ORPHA1957

UMLS via Orphanet ⁷⁴ C0206717

ICD10 via Orphanet ³⁴ C30.0

UMLS ⁷³ C0206717

Sources

Summaries for Olfactory Neuroblastoma

NIH Rare Diseases : ⁵³ Olfactory neuroblastoma is a rare cancer of the upper part of the nasal cavity called the cribiform plate, which is a bone deep in the skull between the eyes, and above the ethmoid sinuses. It accounts for about 5% of all cancers of the nasal cavity and paranasal sinuses. It develops in nerve tissue associated with the sense of smell (olfactory nerve). It can occur at any age, but typically is found in adulthood. Symptoms may be nonspecific and include a blockage of the nasal passageways due to the tumor, facial pain, runny nose, and nosebleeds. Treatment usually includes surgery to remove the tumor, radiation therapy, and sometimes chemotherapy.

MalaCards based summary : Olfactory Neuroblastoma, also known as esthesioneuroblastoma, is related to neuroblastoma and sinonasal undifferentiated carcinoma. An important gene associated with Olfactory Neuroblastoma is SYP (Synaptophysin), and among its related pathways/superpathways are Apoptosis Pathway and Transcriptional misregulation in cancer. The drugs Fentanyl and Fluconazole have been mentioned in the context of this disorder. Affiliated tissues include bone, eye and lung, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : ⁷⁶ Esthesioneuroblastoma, also called "olfactory neuroblastoma", is a rare cancer of the nasal cavity.... more...

Sources

Related Diseases for Olfactory Neuroblastoma

Diseases related to Olfactory Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)

#	Related Disease	Score	Top Affiliating Genes
1	neuroblastoma	31.6	ENO2 NTRK1 NTRK2 SYP
2	sinonasal undifferentiated carcinoma	30.5	ENO2 SYP
3	olfactory groove meningioma	30.1	CHGA SYP
4	cystadenoma	30.1	CHGA SYP
5	central neurocytoma	30.0	CHGA ENO2 SYP
6	paraganglioma	29.9	CHGA ENO2 SYP
7	small cell cancer of the lung	29.7	CHGA ENO2 SSTR2 SYP
8	ganglioneuroma	29.5	CHGA ENO2 NTRK1 NTRK2 SYP
9	ewing sarcoma	29.2	CHGA ENO2 EWSR1 PTPRC S100B SYP
10	nasal cavity olfactory neuroblastoma	12.4
11	causalgia	10.3	ENO2 NTRK1
12	spinal meningioma	10.3	CHGA ENO2
13	spinal canal and spinal cord meningioma	10.3	CHGA ENO2
14	diffuse pulmonary fibrosis	10.3	CHGA ENO2
15	central nervous system benign neoplasm	10.3	ENO2 SYP
16	mixed cell type cancer	10.3	ENO2 SYP
17	adrenal rest tumor	10.3	ENO2 SYP
18	cystic teratoma	10.3	ENO2 SYP
19	optic nerve neoplasm	10.3	ENO2 SYP
20	medullomyoblastoma	10.3	ENO2 SYP
21	adult medulloblastoma	10.3	ENO2 SYP
22	intraocular retinoblastoma	10.3	ENO2 SYP
23	pineal parenchymal tumor of intermediate differentiation	10.3	ENO2 SYP
24	basaloid squamous cell carcinoma	10.3	ENO2 SYP
25	nervous system benign neoplasm	10.2	ENO2 SYP
26	pilomatrixoma	10.2	ENO2 S100B
27	brain injury	10.2	ENO2 S100B
28	traumatic brain injury	10.2	ENO2 S100B
29	spondylosis	10.2	ENO2 S100B
30	granular cell tumor	10.2	ENO2 S100B
31	intracranial primitive neuroectodermal tumor	10.2	CHGA ENO2
32	meningeal melanocytoma	10.2	ENO2 S100B
33	acute mountain sickness	10.2	ENO2 S100B
34	tubular adenocarcinoma	10.2	CHGA SYP
35	gastric tubular adenocarcinoma	10.2	CHGA SYP
36	binswanger's disease	10.2	CHGA SYP
37	carotid body cancer	10.2	ENO2 SYP
38	somatostatinoma	10.2	CHGA ENO2
39	malignant sertoli cell tumor	10.2	ENO2 SYP
40	lung oat cell carcinoma	10.2	CHGA ENO2
41	congenital epulis	10.2	ENO2 NGFR
42	goblet cell carcinoid	10.2	CHGA ENO2
43	pancreatic somatostatinoma	10.2	ENO2 SYP
44	cutaneous ganglioneuroma	10.2	ENO2 SYP
45	anhidrosis	10.2	NGFR NTRK1
46	extrahepatic bile duct adenocarcinoma	10.2	ENO2 SYP
47	papillary tumor of the pineal region	10.2	ENO2 SYP
48	ureter small cell carcinoma	10.2	CHGA SYP
49	ectopic cushing syndrome	10.2	S100B SYP
50	sensory organ benign neoplasm	10.2	ENO2 SYP

Graphical network of the top 20 diseases related to Olfactory Neuroblastoma:

Sources

Symptoms & Phenotypes for Olfactory Neuroblastoma

GenomeRNAi Phenotypes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

²⁶ (show all 18)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased shRNA abundance (Z-score < -2)	GR00366-A-111	9.64	SSTR2
2	Decreased shRNA abundance (Z-score < -2)	GR00366-A-116	9.64	CHGA
3	Decreased shRNA abundance (Z-score < -2)	GR00366-A-139	9.64	NTRK1
4	Decreased shRNA abundance (Z-score < -2)	GR00366-A-179	9.64	SSTR2
5	Decreased shRNA abundance (Z-score < -2)	GR00366-A-20	9.64	NTRK1
6	Decreased shRNA abundance (Z-score < -2)	GR00366-A-200	9.64	SSTR2
7	Decreased shRNA abundance (Z-score < -2)	GR00366-A-203	9.64	EWSR1
8	Decreased shRNA abundance (Z-score < -2)	GR00366-A-216	9.64	EWSR1
9	Decreased shRNA abundance (Z-score < -2)	GR00366-A-53	9.64	CHGA EWSR1 NTRK1 SSTR2
10	Decreased shRNA abundance (Z-score < -2)	GR00366-A-55	9.64	SSTR2
11	Decreased shRNA abundance (Z-score < -2)	GR00366-A-60	9.64	NTRK1
12	Decreased shRNA abundance (Z-score < -2)	GR00366-A-61	9.64	CHGA
13	Decreased shRNA abundance (Z-score < -2)	GR00366-A-65	9.64	CHGA
14	Decreased shRNA abundance (Z-score < -2)	GR00366-A-71	9.64	SSTR2
15	Decreased shRNA abundance (Z-score < -2)	GR00366-A-77	9.64	EWSR1
16	Decreased shRNA abundance (Z-score < -2)	GR00366-A-84	9.64	EWSR1
17	Decreased shRNA abundance (Z-score < -2)	GR00366-A-89	9.64	EWSR1
18	Decreased shRNA abundance (Z-score < -2)	GR00366-A-95	9.64	SSTR2

MGI Mouse Phenotypes related to Olfactory Neuroblastoma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	behavior/neurological	MP:0005386	9.7	ENO2 NGFR NTRK1 NTRK2 S100B SSTR2
2	nervous system	MP:0003631	9.56	CHGA ENO2 NGFR NTRK1 NTRK2 PTPRC
3	normal	MP:0002873	9.1	NGFR NTRK1 NTRK2 PTPRC S100B SYP

Sources

Drugs & Therapeutics for Olfactory Neuroblastoma

Drugs for Olfactory Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Fluconazole

Approved, Investigational

Phase 2, Phase 3

86386-73-4

3365

Miconazole

Approved, Investigational, Vet_approved

Phase 2, Phase 3,Phase 1

22916-47-8

4189

Cevimeline

Approved

Phase 3

107233-08-9

83898 25137844

Megestrol acetate

Approved, Investigational, Vet_approved

Phase 3

595-33-5

11683

Histamine

Approved, Investigational

Phase 3

51-45-6, 75614-87-8

774

Doxepin

Approved, Investigational

Phase 3

1668-19-5

667477 667468

Docetaxel

Approved, Investigational

Phase 3,Phase 1,Phase 2

114977-28-5

148124

Pancreatic Polypeptide

Investigational

Phase 3,Phase 1

59763-91-6

Cola

Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Liver Extracts

Phase 3,Phase 2,Phase 1,Early Phase 1

Anti-Infective Agents

Phase 2, Phase 3,Phase 1

Cytochrome P-450 Enzyme Inhibitors

Phase 2, Phase 3

Central Nervous System Depressants

Phase 3

Adjuvants, Anesthesia

Phase 3

Anesthetics, Intravenous

Phase 3

Analgesics, Opioid

Phase 3

Peripheral Nervous System Agents

Phase 3,Not Applicable

Anesthetics, General

Phase 3

Analgesics

Phase 3

Narcotics

Phase 3

Anesthetics

Phase 3

Steroid Synthesis Inhibitors

Phase 2, Phase 3

Hormone Antagonists

Phase 2, Phase 3,Phase 1

Antifungal Agents

Phase 2, Phase 3,Phase 1

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 2, Phase 3,Phase 1

Hormones

Phase 2, Phase 3,Phase 1

Cytochrome P-450 CYP2C19 Inhibitors

Phase 2, Phase 3

Cytochrome P-450 CYP2C9 Inhibitors

Phase 2, Phase 3

Neurotransmitter Agents

Phase 3,Not Applicable

Cholinergic Agents

Phase 3,Not Applicable

Autonomic Agents

Phase 3,Not Applicable

Muscarinic Agonists

Phase 3

Contraceptive Agents

Phase 3

Megestrol

Phase 3

3562-63-8

19090 3080587

Contraceptives, Oral

Phase 3

Antineoplastic Agents, Hormonal

Phase 3

Central Nervous System Stimulants

Phase 3,Not Applicable

Appetite Stimulants

Phase 3

Histamine Antagonists

Phase 3

Psychotropic Drugs

Phase 3

Antidepressive Agents

Phase 3

Histamine Phosphate

Phase 3

51-74-1

65513

Antidepressive Agents, Tricyclic

Phase 3

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Ritonavir

Approved, Investigational

Phase 2

155213-67-5

392622

Indinavir

Approved

Phase 2

150378-17-9

5362440

Bevacizumab

Approved, Investigational

Phase 2,Phase 1

216974-75-3

Cetuximab

Approved

Phase 1, Phase 2

205923-56-4

56842117 2333

Carboplatin

Approved

Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Interventional clinical trials:

(show top 50) (show all 65)

#	Name	Status	NCT ID	Phase	Drugs
1	Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain	Completed	NCT00538850	Phase 3	Fentanyl sublingual spray;Placebo
2	Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer	Completed	NCT00090337	Phase 3
3	Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer	Completed	NCT00002533	Phase 2, Phase 3	fluconazole
4	Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer	Completed	NCT00017511	Phase 3	cevimeline hydrochloride
5	Megestrol to Limit Weight Loss and Improve Quality of Life in Treating Patients With Head and Neck Cancer	Completed	NCT00006799	Phase 3	megestrol acetate
6	Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy	Completed	NCT01156142	Phase 3	doxepin hydrochloride
7	Docetaxel and St. John's Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	Withdrawn	NCT00041171	Phase 3	Hypericum perforatum;docetaxel
8	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases	Unknown status	NCT00637637	Phase 2	indinavir sulfate;ritonavir
9	Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer	Completed	NCT00492089	Phase 2	bevacizumab;placebo
10	Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer	Completed	NCT00101348	Phase 1, Phase 2	erlotinib hydrochloride
11	Chemotherapy in Treating Patients With Solid Tumors	Completed	NCT00003103	Phase 1, Phase 2	docetaxel
12	High-dose ICE With Amifostine	Completed	NCT00003657	Phase 2	Amifostine;Carboplatin;Etoposide;Ifosfamide
13	Docetaxel in Treating Patients With Solid Tumors	Completed	NCT00003565	Phase 2	docetaxel
14	Oxaliplatin and Capecitabine in Treating Patients With Relapsed or Metastatic Head and Neck Cancer	Completed	NCT00448552	Phase 2	capecitabine;oxaliplatin
15	Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor	Completed	NCT00021047	Phase 1, Phase 2	capecitabine;carboplatin;epirubicin hydrochloride
16	Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors	Completed	NCT00019331	Phase 2	DetoxPC
17	Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients With Central Nervous System Cancer	Completed	NCT00007982	Phase 2	carmustine;cisplatin;cyclophosphamide;etoposide;thiotepa
18	Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer	Completed	NCT00509665	Phase 2	doxorubicin hydrochloride;gemcitabine hydrochloride
19	Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer	Completed	NCT00021333	Phase 2	cisplatin;paclitaxel
20	A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages	Recruiting	NCT03274414	Phase 2	Cisplatin;cisplatin and etoposide
21	Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients	Active, not recruiting	NCT02099188	Phase 2	Cisplatin;Docetaxel;5-fluorouracil;Etoposide;Adriamycin;Ifosfamide;Leucovorin
22	Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients	Active, not recruiting	NCT02099175	Phase 2	Cisplatin;Docetaxel;5-fluorouracil;Etoposide;Adriamycin;Ifosfamide;Leucovorin
23	18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy	Active, not recruiting	NCT01806675	Phase 1, Phase 2	fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
24	Functional MRI in Finding Hypoxia in Patients Undergoing Chemotherapy and Radiation Therapy for Stage III or Stage IV Head and Neck Cancer	Unknown status	NCT00896350	Phase 1	chemotherapy
25	Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer	Completed	NCT01637194	Phase 1	everolimus
26	Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer	Completed	NCT00470496	Phase 1	HPPH;photodynamic therapy
27	Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer	Completed	NCT00023959	Phase 1	hydroxyurea;fluorouracil
28	Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors	Completed	NCT00089362	Phase 1	alvespimycin hydrochloride
29	Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer	Completed	NCT00397384	Phase 1	cetuximab;erlotinib hydrochloride
30	7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)	Completed	NCT00031681	Phase 1	7-hydroxystaurosporine;irinotecan hydrochloride
31	Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction	Completed	NCT00030498	Phase 1	erlotinib hydrochloride
32	Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors	Completed	NCT01172028	Phase 1	Taxotere (Docetaxel);Alimta (Pemetrexed)
33	Liposomal Lurtotecan Plus Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors	Completed	NCT00006036	Phase 1	cisplatin;lurtotecan liposome
34	Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function	Completed	NCT00002901	Phase 1	docetaxel
35	Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer	Completed	NCT00045006	Phase 1	vorinostat
36	MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma	Completed	NCT00020579	Phase 1	entinostat
37	Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer	Completed	NCT00019110	Phase 1
38	Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors	Completed	NCT00010023	Phase 1	capecitabine;cisplatin
39	Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer	Completed	NCT00004065	Phase 1	tanespimycin
40	NGR-TNF in Treating Patients With Advanced Solid Tumors	Completed	NCT00098943	Phase 1
41	Thalidomide and Docetaxel in Treating Patients With Advanced Cancer	Completed	NCT00049296	Phase 1	docetaxel;thalidomide
42	Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors	Completed	NCT00014456	Phase 1	docetaxel;gemcitabine hydrochloride
43	SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck	Completed	NCT00005647	Phase 1	paclitaxel;semaxanib
44	Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer	Terminated	NCT00002947	Phase 1
45	Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin	Terminated	NCT00023790	Phase 1	silicon phthalocyanine 4
46	S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors	Withdrawn	NCT00937417	Phase 1	docetaxel;vandetanib
47	MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer	Unknown status	NCT00984074
48	Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer	Completed	NCT00068497	Not Applicable	gefitinib
49	Customized Headrest or Standard Headrest in Holding Patients Still While Undergoing Radiation Therapy for Head and Neck Cancer	Completed	NCT00973947	Not Applicable
50	Collecting and Storing Tissue Samples From Patients With Head and Neck Cancer	Completed	NCT00898300

Search NIH Clinical Center for Olfactory Neuroblastoma

Cochrane evidence based reviews: esthesioneuroblastoma, olfactory

Sources

Genetic Tests for Olfactory Neuroblastoma

Sources

Anatomical Context for Olfactory Neuroblastoma

MalaCards organs/tissues related to Olfactory Neuroblastoma:

⁴¹

Bone, Eye, Lung, Brain, Kidney, Lymph Node, Thyroid

Sources

Publications for Olfactory Neuroblastoma

Articles related to Olfactory Neuroblastoma:

(show top 50) (show all 650)

#	Title	Authors	Year
1	Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. ( 30466166 )	Joshi RR...Cohen MA	2019
2	DNA methylation-based reclassification of olfactory neuroblastoma. ( 29730775 )	Capper D....SchA1ller U.	2018
3	Surgical Treatment of Olfactory Neuroblastoma: Major Complication Rates, Progression Free and Overall Survival. ( 29868319 )	Wertz A....McKean E.L.	2018
4	Olfactory Neuroblastoma. ( 29411144 )	Abdelmeguid A.S.	2018
5	Sinonasal Neuroendocrine Neoplasms: Current Challenges and Advances in Diagnosis and Treatment, with a Focus on Olfactory Neuroblastoma. ( 29427030 )	Bell D.	2018
6	Age distribution and age-related outcomes of olfactory neuroblastoma: a population-based analysis. ( 29881306 )	Yin Z....Yuan Z.	2018
7	Ectopic Cushing's syndrome secondary to olfactory neuroblastoma. ( 29340776 )	Yu K....Gnanalingham K.	2018
8	Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review. ( 29901583 )		2018
9	An unusual manifestation of olfactory neuroblastoma. ( 29535093 )		2018
10	Clinical features and the molecular biomarkers of olfactory neuroblastoma. ( 29921494 )		2018
11	Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review: Erratum. ( 29995829 )		2018
12	Hyperostotic esthesioneuroblastoma as a fibrous dysplasia mimicker. ( 29789119 )	Calvo-Henr?quez C...Rosario-Ortiz A	2018
13	Patterns of failures after surgical resection in olfactory neuroblastoma. ( 30506150 )	Kim N...Suh CO	2018
14	Olfactory neuroblastoma treated with minimally invasive surgery and adjuvant radiotherapy: a case report and review of the literature. ( 30363190 )	Cante D...La Porta MR	2018
15	Ectopic adrenocorticotropic hormone syndrome associated with olfactory neuroblastoma: acquirement of adrenocorticotropic hormone expression during disease course as shown by serial immunohistochemistry examinations. ( 30392451 )	Kadoya M...Koyama H	2018
16	Non-contiguous Meningeal Recurrence of Olfactory Neuroblastoma: A Case Report and Literature Review. ( 30023143 )	Saito A...Uenohara H	2018
17	Endonasal endoscopic resection of olfactory neuroblastoma: an 11-year experience. ( 30074458 )	Gallia GL...Ishii M	2018
18	Correction to: DNA methylation-based reclassification of olfactory neuroblastoma. ( 30094618 )	Capper D...Sch?ller U	2018
19	Pulmonary nocardiosis mimicking small cell lung cancer in ectopic ACTH syndrome associated with transformation of olfactory neuroblastoma: a case report. ( 30134888 )	Kobayashi K...Betsuyaku T	2018
20	Patient characteristics of olfactory neuroblastoma: experience from a tertiary cancer centre 2000-2016 covering Eastern Denmark. ( 30168622 )	Gram SB...von Buchwald C	2018
21	Olfactory Neuroblastoma: A Rare Cause of External Ophthalmoplegia, Proptosis and Compressive Optic Neuropathy. ( 29755824 )	Kart? ?...K?sbeci T	2018
22	Intracranial immature teratoma invading the nasal cavity mimicking olfactory neuroblastoma: A case report. ( 29995824 )	Jiang Y...Fan C	2018
23	A Case of Cushing's Syndrome due to Ectopic Adrenocorticotropic Hormone Secretion from Esthesioneuroblastoma with Long Term Follow-Up after Resection. ( 29515922 )	Matheny LN...Bao S	2018
24	Endoscopic endonasal management of esthesioneuroblastoma: A retrospective multicenter study. ( 28595773 )	Nakagawa T...Omori K	2018
25	Intranasal Esthesioneuroblastoma: CT Patterns Aid in Preventing Routine Nasal Polypectomy. ( 29217745 )	Peckham ME...Harnsberger HR	2018
26	Endoscopic endonasal resection of sinonasal/anterior skull base malignancy (Kadish C esthesioneuroblastoma). ( 29277853 )	Mehta GU...Raza SM	2018
27	Exploration of the optimal treatment regimes for Esthesioneuroblastoma: a single center experience in China. ( 29290783 )	Yuan Y...Ren Y	2018
28	High 18F-FDG Avidity of Low-Grade Esthesioneuroblastoma. ( 29293141 )	Jannin A...Do Cao C	2018
29	An Uncommon Case of Pediatric Esthesioneuroblastoma Presenting as SIADH: 18F-FDG PET/CT in Staging and Post-Therapeutic Assessment. ( 29342907 )	Fosb?l M?...Borgwardt L	2018
30	Dural recurrence among esthesioneuroblastoma patients presenting with intracranial extension. ( 29427378 )	Yu Y...Yom SS	2018
31	Treatment of pediatric esthesioneuroblastoma with smell preservation. ( 29475764 )	Maggiore G...Gallo O	2018
32	Esthesioneuroblastoma: A Patterns-of-Care and Outcomes Analysis of the National Cancer Database. ( 29481629 )	Orton A...Hitchcock YJ	2018
33	Neuroradiological and Neuropathological Changes After 177Lu-Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma. ( 29554305 )	Schneider JR...Boockvar JA	2018
34	Bilateral Adrenal Hyperplasia Due to Adrenocorticotropic Hormone-Secreting Esthesioneuroblastoma on FDG PET and 111In-Pentetreotide Scintigraphy. ( 29659387 )	Matsusaka Y...Jinzaki M	2018
35	Esthesioneuroblastoma with distant metastases: Systematic review & meta-analysis. ( 29756250 )	Marinelli JP...Chintakuntlawar AV	2018
36	Changing Trends in the Management of Esthesioneuroblastoma: Irish and International Perspectives. ( 29765824 )	Woods RSR...Lacy PD	2018
37	An Unusual Presentation of Esthesioneuroblastoma in a Young Pregnant Female. ( 29765954 )	Wadhwani M...Das P	2018
38	Esthesioneuroblastoma metastatic to the breast. ( 29781189 )	Moalla S...Mezghani Boussetta S	2018
39	Esthesioneuroblastoma and Olfactory Preservation: Is it Reasonable to Attempt Smell Preservation? ( 29868325 )	Gompel JJV...Link MJ	2018
40	Esthesioneuroblastoma with widespread distant metastasis: Case report and literature review. ( 29940688 )	Khosla M...Sue R	2018
41	Dural Invasion Predicts the Laterality and Development of Neck Metastases in Esthesioneuroblastoma. ( 30210978 )	Marinelli JP...Price DL	2018
42	Endoscopic management of Esthesioneuroblastoma: Our experience and review of the literature. ( 30340976 )	Klironomos G...Gentili F	2018
43	Advanced Radiation Techniques in the Treatment of Esthesioneuroblastoma: A 7-Year Single-Institution's Clinical Experience. ( 30463343 )	Liermann J...Adeberg S	2018
44	Utility of adjuvant chemotherapy in patients receiving surgery and adjuvant radiotherapy for primary treatment of esthesioneuroblastoma. ( 30536472 )	Miller KC...Chintakuntlawar AV	2018
45	Comprehensive Molecular Profiling of Olfactory Neuroblastoma Identifies Potentially Targetable FGFR3 Amplifications. ( 28775129 )	Lazo de la Vega L....Harms P.W.	2017
46	Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: Series report and literature review. ( 29061289 )	Bartel R....Manos M.	2017
47	The clinicopathological spectrum of olfactory neuroblastoma and sinonasal neuroendocrine neoplasms: Refinements in diagnostic criteria and impact of multimodal treatments on survival. ( 29103747 )	Turri-Zanoni M....La Rosa S.	2017
48	Olfactory Neuroblastoma with Divergent Differentiation: An Unusual Histologic Finding in a Rare Tumor. ( 28168398 )	Meyer C....Mitchell A.	2017
49	Proton beam therapy for olfactory neuroblastoma. ( 28062086 )	Nakamura N....Akimoto T.	2017
50	Long-term control of olfactory neuroblastoma in a dog treated with surgery and radiation therapy. ( 28653386 )	Gumpel E....Taylor D.P.	2017

Sources

Genes for Olfactory Neuroblastoma

Genes related to Olfactory Neuroblastoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	SYP	Synaptophysin	Protein Coding	32.31	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9548430
2	ENO2	Enolase 2	Protein Coding	31.25	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9548430
3	NTRK1	Neurotrophic Receptor Tyrosine Kinase 1	Protein Coding	26.51	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19386345 12934398 12175342
4	S100B	S100 Calcium Binding Protein B	Protein Coding	23.5	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	1700595 8630875
5	CHGA	Chromogranin A	Protein Coding	22.51	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	SSTR2	Somatostatin Receptor 2	Protein Coding	20.85	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	EWSR1	EWS RNA Binding Protein 1	Protein Coding	20.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	PTPRC	Protein Tyrosine Phosphatase, Receptor Type C	Protein Coding	20.29	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	NGFR	Nerve Growth Factor Receptor	Protein Coding	20.27	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
10	NTRK2	Neurotrophic Receptor Tyrosine Kinase 2	Protein Coding	19.88	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Olfactory Neuroblastoma

Copy number variations for Olfactory Neuroblastoma from CNVD:

⁷ (show all 31)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	31526	1	28000000	30200000	Gain		Olfactory neuroblastoma
2	34250	1	5400000	7200000	Gain		Olfactory neuroblastoma
3	41470	10	18700000	22600000	Gain		Olfactory neuroblastoma
4	63735	12	120700000	125900000	Gain		Olfactory neuroblastoma
5	74688	13	110300000	115169878	Gain	CUL4A	Olfactory neuroblastoma
6	74689	13	110300000	115169878	Gain	TFDP1	Olfactory neuroblastoma
7	75167	13	17900000	115169878	Gain		Olfactory neuroblastoma
8	77744	13	47300000	55300000	Gain		Olfactory neuroblastoma
9	79881	13	79000000	87700000	Gain		Olfactory neuroblastoma
10	91527	15	31200000	33600000	Gain		Olfactory neuroblastoma
11	101890	16	47000000	52600000	Gain		Olfactory neuroblastoma
12	150427	20	1	27500000	Gain		Olfactory neuroblastoma
13	151980	20	27500000	63025520	Gain		Olfactory neuroblastoma
14	152120	20	29400000	37600000	Gain		Olfactory neuroblastoma
15	154980	20	5100000	12100000	Gain		Olfactory neuroblastoma
16	155529	20	56500000	63025520	Gain	BRK	Olfactory neuroblastoma
17	159453	21	42600000	48129895	Gain		Olfactory neuroblastoma
18	163221	22	25900000	29600000	Gain		Olfactory neuroblastoma
19	179990	4	1	6000000	Gain		Olfactory neuroblastoma
20	181394	4	120800000	191154276	Gain		Olfactory neuroblastoma
21	184608	4	17800000	48200000	Gain		Olfactory neuroblastoma
22	187607	4	52700000	59500000	Gain		Olfactory neuroblastoma
23	190046	4	82400000	93700000	Gain		Olfactory neuroblastoma
24	196156	5	159900000	168500000	Gain		Olfactory neuroblastoma
25	196538	5	168500000	180915260	Gain		Olfactory neuroblastoma
26	213457	6	46200000	51800000	Gain		Olfactory neuroblastoma
27	227898	7	72200000	77500000	Gain	FZD9	Olfactory neuroblastoma
28	227899	7	72200000	77500000	Gain	LIMK1	Olfactory neuroblastoma
29	228591	7	77500000	86400000	Gain		Olfactory neuroblastoma
30	251884	9	33200000	36300000	Gain		Olfactory neuroblastoma
31	257109	X	1	155270560	Gain		Olfactory neuroblastoma

Sources

Expression for Olfactory Neuroblastoma

Search GEO for disease gene expression data for Olfactory Neuroblastoma.

Sources

Pathways for Olfactory Neuroblastoma

Pathways related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Apoptosis Pathway ⁷² Show member pathways Akt Pathway ⁷² NF-kappaB Pathway ⁷²	12.03	NGFR NTRK1 NTRK2
2	Transcriptional misregulation in cancer ³⁷	11.85	EWSR1 NGFR NTRK1
3	Brain-Derived Neurotrophic Factor (BDNF) signaling pathway ¹	11.7	NGFR NTRK1 NTRK2
4	Neuroscience ⁴	11.63	ENO2 NGFR NTRK1 NTRK2 S100B SYP
5	Guidance Cues and Growth Cone Motility ⁶⁴	11.57	NGFR NTRK1 NTRK2
6	Neurotrophic factor-mediated Trk receptor signaling ¹ Show member pathways Signalling to STAT3 ⁶⁶ TRKA activation by NGF ⁶⁶	11.12	NGFR NTRK1 NTRK2
7	Microglia Activation During Neuroinflammation: Steady-State Microglia ⁶⁵	10.79	NTRK1 NTRK2 PTPRC
8	Activation of TRKA receptors ⁶⁶ Show member pathways NGF-independant TRKA activation ⁶⁶	10.3	NTRK1 NTRK2

Sources

GO Terms for Olfactory Neuroblastoma

Cellular components related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	integral component of plasma membrane	GO:0005887	9.02	NGFR NTRK1 NTRK2 PTPRC SSTR2

Biological processes related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of ERK1 and ERK2 cascade	GO:0070374	9.63	NTRK1 NTRK2 PTPRC
2	cellular response to nerve growth factor stimulus	GO:1990090	9.43	NTRK1 NTRK2
3	positive regulation of axonogenesis	GO:0050772	9.4	NGFR NTRK2
4	cellular response to amyloid-beta	GO:1904646	9.37	NGFR NTRK1
5	regulation of neuronal synaptic plasticity	GO:0048168	9.32	S100B SYP
6	mechanoreceptor differentiation	GO:0042490	9.26	NTRK1 NTRK2
7	positive regulation of MAPK cascade	GO:0043410	9.26	NGFR NTRK1 NTRK2 PTPRC
8	neurotrophin signaling pathway	GO:0038179	9.16	NTRK1 NTRK2
9	neurotrophin TRK receptor signaling pathway	GO:0048011	8.8	NGFR NTRK1 NTRK2

Molecular functions related to Olfactory Neuroblastoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transmembrane signaling receptor activity	GO:0004888	9.43	NGFR NTRK1 NTRK2
2	nerve growth factor binding	GO:0048406	9.16	NGFR NTRK1
3	neurotrophin receptor activity	GO:0005030	8.96	NTRK1 NTRK2
4	neurotrophin binding	GO:0043121	8.8	NGFR NTRK1 NTRK2

Sources

Sources for Olfactory Neuroblastoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia